Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143737 | 0.94 | TP53 (0.44) | MAPTMEN1KMT2ATP53 | |
| SCHEMBL1143956 | 0.92 | MEN1 (0.39) | MAPTMEN1KMT2ATP53JAK2 | |
| SCHEMBL1143601 | 0.91 | PDE4A (0.41) | MAPTMEN1KMT2ATP53JAK2 | |
| SCHEMBL1144302 | 0.90 | PDE4A (0.41) | MAPTMEN1KMT2ATP53JAK2 | |
| SCHEMBL1143748 | 0.89 | MAPT (0.37) | MAPTMEN1KMT2ATP53JAK2 | |
| Cyclopropane SCHEMBL4211055 | 0.89 | MEN1 (0.41) | MAPTMEN1KMT2ATP53TDP1 | |
| SCHEMBL1143639 | 0.86 | PDE4A (0.42) | MAPTMEN1KMT2ATP53POLB | |
| SCHEMBL5496470 | 0.85 | NR1I2 (0.42) | MAPTTP53POLB | |
| SCHEMBL1143520 | 0.85 | PDE4B (0.49) | MAPTMEN1KMT2ATP53 | |
| SCHEMBL1143947 | 0.85 | PDE4A (0.46) | MAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158672-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158672-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158672-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-7893102-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893102-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893102-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090143382-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-20090143382-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-7504427-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504427-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | TRIMERIS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | TRIMERIS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-7173058-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173058-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | PDE4A, PDE4B, PDE4D | MAPT 2692/4885MEN1 3642/4885KMT2A 4643/4885 |
| US-20090143382-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | PDE4A, PDE4B, PDE4D | MAPT 2692/4885MEN1 3642/4885KMT2A 4643/4885 |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | MAPT 2692/4885MEN1 3642/4885KMT2A 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.